Polygon Therapeutics shares recent achievements and acceleration for a First In Human in 2025

 ‍

·   Lead candidate PLG-101 has successfully met all pre-clinical milestonesand is advancing to clinical development, with Phase I scheduled for late 2025.‍

·   The scientific advisory board is expanding internationally.

·   The Series A is planned following the completionof the seed-financing.

Paris, November 8^th 2024 — Polygon Therapeutics, a French biotech company specializing in cardio-immunology, is proud to announce significant advancements in the development of its innovative biopharmaceutical aimed at treating acute cardiovascular diseases. With the goal of starting clinical trials in 2025, the company is rapidly accelerating its R&D and manufacturing efforts to bring its novel therapy closer to patients.

Advancement Toward Clinical Trials  

Polygon Therapeutics has successfully tested and validated its lead therapeutic candidate through comprehensive in vitro and in vivo studies. These promising results lay the foundation for the next critical phase: clinical trials in humans. The company is now finalizing the scale-up process necessary for the manufacturing of this first-in-class drug, ensuring that production is ready for upcoming trials.

"Our lead candidate, PLG-101, has passed all the milestones in preclinical studies, and we are now focused on moving rapidly toward clinical development in acute myocardial infarction”, said Mohamed ABOU ALI, CEO of Polygon Therapeutics. "Our disease modifying approach in acute cardiology is designed to impact mid-term consequences such as a 10% mortality at 12 months. 2025 will be a pivotal year, as we see a renewed interest for our positioning following recent transactions in the field.”

Strategic Reinforcement with InternationalBoard

In preparation for this acceleration, Polygon Therapeutics has strengthened its governance by assembling an esteemed international board of experts in cardiovascular medicine. The board will play a critical role in guiding the company's clinical strategy and global expansion efforts.

Members include notably:  

  ·  Prof. Peter Libby – Mallinckrodt Professor of Medicine at Harvard Medical School and KOL in cardio-immunology. Prof. Libby has received numerous prestigious awards for his work on the role of inflammation in vascular diseases and is recognized as a leading cardiologist globally with funding from the American Heart Association and the National Institutes of Health.

  ·   Prof. Faiez Zannad – Professor in Cardiology and KOL in Cardiovascular Clinical Trials. He is the founder & chairman of the annual Global Cardiovascular Clinical Trialists Forum (CVCT) that brings together cardiologists, researchers, regulators and industry professionals to discuss advancements, challenges, and innovations in cardiovascular clinical trials.

  ·   Prof. Tabassome Simon – Professor in Pharmacology and KOL in Clinical Trials. She heads the Clinical Pharmacology department at Hospital Saint-Antoine AP-HP. Recently, she has been chosen by the board of the European Association of Clinical Pharmacology and Therapeutics to receive the "Lifetime Achievement Award".

Funding and Financial Growth

Polygon Therapeutics recently completed its seed financing round at $7.5M. This financing will bring the company to the threshold of clinical trials. In parallel, Polygon is preparing a Series A funding round to support the first phases of clinical trials both in Europe and the United States. The company aims to secure the capital needed to progress through early-stage trials, with plans to expand its operations globally.

About Polygon Therapeutics

Founded in 2021, Polygon Therapeutics is a pioneering French biotech specializing in cardio-immunology. The company explores the dynamic interplay between the immune system and cardiovascular health to develop novel and targeted immunotherapies for acute cardiovascular diseases. Backed by a distinguished Scientific Advisory Board and an expert team, Polygon operates from its headquarters in Paris and its research unit at the Paris Cardiovascular Research Center (PARCC).

About PLG-101

PLG-101, the first in class human anti-CD8 depleting antibody, was designed to prevent the high mortality and morbidity following acute myocardial infarction (AMI), affecting 1.9M patients per year in the USA and Europe. High-risk AMI patients have a 10% mortality at 12 months despite the availability of well-established standard of care in developed countries. The role of the immune system, and particularly the CD8+ T cells, in exacerbating the damage to the infarcted and surrounding tissues in the weeks following the reperfusion is now well established. PLG-101 has demonstrated in in vivo models its capacity to reduce the infarct size by 60% and improve the heart function by 25% without any side effect. PLG-101 is an anti-CD8 monoclonal antibody administered in one single injection during the reperfusion procedure.

‍

For more information, please contact:

Tatiana MONSEUR

COO & CFO

Tatiana.monseur@polygon.care